Table 1 Participant characteristics
Participant characteristics | Furosemide naïve | Chronic furosemide | p-value |
|---|---|---|---|
(n = 23) | (n = 15) | ||
Age (years) | 68 ± 8 | 69 ± 10 | 0.49 |
Race | 0.28 | ||
White (%) | 78 | 67 | |
African American (%) | 22 | 33 | |
Gender (% male) | 35 | 40 | 0.65 |
Body mass index (kg/m2) | 29.4 ± 6.5 | 30.3 ± 7.1 | 0.56 |
GFR (mL/min/1.73 m2) | 60.1 ± 31.6 | 44.6 ± 14.7 | 0.005* |
Renal artery stenosis (mean,%) | |||
Left | 26 | 24 | 0.70 |
Right | 26 | 21 | 0.82 |
Renal blood flow (mean, ml/min) | |||
Left | 187 | 127 | 0.17 |
Right | 231 | 196 | 0.50 |
Chronic kidney disease stage (n) | 0.01* | ||
Stage 1 (GFR > 90) | 5 (22%) | 0 (0%) | |
Stage 2 (GFR 60-89) | 5 (22%) | 2 (13%) | |
Stage 3 (GFR 30-59) | 9 (39%) | 9 (60%) | |
Stage 4 (GFR 15-29) | 4 (17%) | 4 (27%) | |
Stage 5 (GFR < 15) | 0 (0%) | 0 (0%) | |
Hypertension diagnosis (%) | 91 | 100 | 0.25 |
Number of antihypertensive meds (n) | 2.7 ± 1.6 | 4.3 ± 1.0 | 0.0001* |
Hemoglobin (g/dL) | 12.7 ± 2.3 | 12.1 ± 1.8 | 0.25 |
Diabetes diagnosis (%) | 30 | 60 | 0.01* |
Patients on statin therapy (%) | 65 | 73 | 0.45 |
Patients on ACEI’s or ARB’s (%) | 65 | 33 | 0.006* |